Results 101 to 110 of about 376,342 (317)

Flow Enabled Target Capture Halbach‐based magnetic enrichment increases circulating tumor cell capture from blood in metastatic cancer patients

Molecular Oncology, EarlyView.
Pair‐wise comparison of the CellSearch and FETCH enrichment technologies for circulating tumor cells (CTCs) from metastatic breast, prostate, and small cell lung cancer patients shows an increased capture of CTCs using FETCH enrichment. The clinical implementation of circulating tumor cells (CTCs) as a predictive tool for therapy efficacy in the ...
Michiel Stevens, Anouk Mentink, Tom Niessink, Frank Coumans, Leonie Mekenkamp, Ruchi Bansal, Jeroen Hiltermann   +6 more
wiley   +1 more source

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

What Can Be Learnt about Disease Progression in Breast Cancer Dormancy from Relapse Data? [PDF]

, 2013
Breast cancer patients have an anomalously high rate of relapse many years-up to 25 years-after apparently curative surgery removed the primary tumour.
Karen M Page, Alarcón, T, Tomlinson, IP, Page, KM, Lisa Willis (410078), Tomás Alarcón (224873), Ian P. M. Tomlinson (218767), Tomlinson Ian P. M., Karen M. Page (410080), Trevor A Graham, Alison Malcolm R., Alarcón Tomás, Page Karen M., Tomás Alarcón, Malcolm R. Alison (201259), Willis Lisa, Trevor A. Graham (410079), Graham, TA, Alison, MR, Malcolm R Alison, Tomlinson, IPM, Willis, L, Lisa Willis, Graham Trevor A., Ian P M Tomlinson   +24 more
core   +1 more source

Longitudinal genome‐wide aneuploidy measurements in circulating cell‐free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer

Molecular Oncology, EarlyView.
Many patients with urothelial cancer do not benefit from treatment with pembrolizumab, while at risk of severe side effects. Changes in the levels of circulating tumor DNA early during treatment, measured by a simple and affordable assay that can be easily implemented in the clinic, can be used as a prognostic tool to identify these patients.
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, Iris te Paske, Vanja de Weerd, Corine M. Beaufort, Hans M. Westgeest, Jens Voortman, Maureen J. B. Aarts, Maud Rijnders, Astrid A. M. van der Veldt, Ronald de Wit, Niven Mehra, Saskia M. Wilting, Debbie G. J. Robbrecht   +14 more
wiley   +1 more source

MITF maintains genome stability in nonmelanocyte lineages

Molecular Oncology, EarlyView.
MITF is essential for melanocyte survival and acts as an oncogene in 10%–20% of melanomas. We show that MITF depletion causes genome instability in nonmelanocytic cells, leading to LATS2‐mediated P53 activation, cell cycle arrest, and apoptosis. This study highlights the role of MITF as a genome maintenance factor beyond the melanocyte lineage. Created
Drifa H. Gudmundsdottir, Adrián López García de Lomana, Thejus B. Venkatesh, Kritika Kirty, Snaevar Sigurdsson, Linda Vidarsdottir, Ramile Dilshat, Erla Sveinbjornsdottir, Snaedis Ragnarsdottir, Daniel H Magnusson, Maria R. Bustos, Eirikur Steingrimsson, Thorkell Gudjonsson, Stefan Sigurdsson   +13 more
wiley   +1 more source

Changing the Landscape for People Living with Metastatic Breast Cancer: Metastatic Breast Cancer Landscape Analysis - Research Report October 2014 [PDF]

, 2014
40,000 women and men in America every year and 20-30% of those diagnosed with early stage breast cancer will go on to develop recurrent, metastatic disease.

core  

Distinguished biomimetic dECM system facilitates early detection of metastatic breast cancer cells

Bioengineering & Translational Medicine
Breast cancer is the most prevalent malignant tumor affecting women's health. Bone is the most common distant metastatic organ, worsening the quality of life and increasing the mortality of patients.
Bowen Weng, Mei Li, Weilai Zhu, Jing Peng, Xufeng Mao, Yanan Zheng, Chi Zhang, Senhao Pan, Haijiao Mao, Jiyuan Zhao   +9 more
doaj   +1 more source

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

Molecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka, Wioleta Cieślik, Wojciech Płaziński, Katarzyna Stępnik, Anna Boguszewska‐Czubara, Elżbieta Kot, Robert Musioł, Mateusz Jasica, Anna Mrozek‐Wilczkiewicz, Katarzyna Malarz   +9 more
wiley   +1 more source

Phosphorylated c-Src in the nucleus is associated with improved patient outcome in ER-positive breast cancer [PDF]

, 2008
Elevated c-Src protein expression has been shown in breast cancer and <i>in vitro</i> evidence suggests a role in endocrine resistance. To investigate whether c-Src is involved in endocrine resistance, we examined the expression of both total
Cooke, T.G., Tatarov, O., Tovey, S, O Tatarov, V Brunton, T G Cooke, McDuff, E, E J Campbell, McDuff, E., Tovey, S., Edwards, J, E McDuff, Brunton, V.G., S Tovey, Brunton, V, J Edwards, Edwards, J., Campbell, E J, Tatarov, O, Campbell, E.J., Cooke, T G   +20 more
core   +1 more source

SUBMIT: Systemic therapy with or without up front surgery of the primary tumor in breast cancer patients with distant metastases at initial presentation

BMC Surgery, 2012
Background Five percent of all patients with breast cancer have distant metastatic disease at initial presentation. Because metastatic breast cancer is considered to be an incurable disease, it is generally treated with a palliative intent.
Ruiterkamp Jetske, Voogd Adri C, Tjan-Heijnen Vivianne CG, Bosscha Koop, van der Linden Yvette M, Rutgers Emiel, Boven Epie, van der Sangen Maurice JC, Ernst Miranda F   +8 more
doaj   +1 more source